Alendronate/calcitriol - Yuyu Pharma

Drug Profile

Alendronate/calcitriol - Yuyu Pharma

Alternative Names: Maxmarvil

Latest Information Update: 06 Jan 2016

Price : $50

At a glance

  • Originator Yuyu
  • Class Antihyperglycaemics; Bisphosphonates; Calcium regulators; Cholestenes; Osteoporosis therapies; Small molecules; Sterols; Vitamin D analogues
  • Mechanism of Action Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Osteoporosis

Most Recent Events

  • 01 Jan 2012 Launched for Osteoporosis in Thailand (PO)
  • 01 Jan 2004 Launched for Osteoporosis in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top